Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen

DRUG4 trials

Sponsors

Novo Nordisk A/S

Conditions

Participants with T2D and overweightType 1 DiabetesType 2 DiabetesType 2 diabetes

Phase 3

A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec when Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes

CompletedCTIS2023-506084-34-00

Novo Nordisk A/SType 2 Diabetes

Start: 2024-04-12End: 2025-06-13Target: 145Updated: 2025-04-17

Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight

CompletedCTIS2024-510612-75-00

Novo Nordisk A/SParticipants with T2D and overweight

Start: 2022-08-31End: 2025-04-01Target: 398Updated: 2025-03-12

A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination with Insulin Aspart, in Adults with Type 1 Diabetes

RecruitingCTIS2024-519945-31-00

Novo Nordisk A/SType 1 Diabetes

Start: 2025-08-21Target: 242Updated: 2025-10-15

Phase 4

EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-naïve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study

Not yet recruitingCTIS2024-520068-32-00

Novo Nordisk A/SType 2 diabetes

Target: 204Updated: 2026-01-12